InMode Ltd. to Report Record Q3 Revenue

Trending News 🌥️

InMode Ltd. is a medical technology company that designs, develops, and markets radiofrequency-based medical systems. The company is set to release its Q3 earnings report on October 27th. The company has recently raised its full-year revenue guidance while expecting record revenue in Q3. InMode’s products are used in a variety of cosmetic procedures, including body contouring, skin tightening, and fat reduction. The company’s products are also used in a number of surgical procedures, such as ablation, tissue coagulation, and hemostasis. InMode’s products are sold to physicians and aesthetic clinics worldwide.

The company has a strong presence in the United States, Europe, and Asia. InMode’s products are backed by a number of clinical studies and have been featured in several peer-reviewed journals. InMode is led by a team of experienced medical professionals and engineers. The company’s products are FDA-cleared and CE-marked. InMode is a publicly traded company listed on the Nasdaq Stock Market.

Earnings

INMODE ($NASDAQ:INMD): InMode Ltd., a global medical technology company, announced that it will report record revenue for the third quarter of its fiscal year 2022. In its latest earning report, the company reported total revenue of 404.2 million USD for the quarter ending June 30, an increase of 13.0% over the same period last year.

Additionally, net income for the quarter was 172.4 million USD, an increase of 4.5% over the same period last year. The company attributes this growth to strong demand for its products and continued investment in research and development. InMode Ltd. is committed to providing innovative solutions that improve the lives of patients and their families.

Price History

The company attributed the strong results to strong demand for its products and continued growth in its international markets. InMode’s stock price rose 5.3% on the news, reaching $34.9 per share. Analysts believe that the company’s strong performance will continue in the quarters to come. InMode is well-positioned to capitalize on the growing global demand for minimally invasive aesthetic treatments.

The company’s products are popular among patients and doctors alike because they offer excellent results with minimal downtime and side effects. InMode’s technology is constantly evolving, and the company is always introducing new and innovative products to the market. With its strong financial position and bright future prospects, InMode is poised for continued success in the years to come.

VI Analysis

Inmode Ltd.’s fundamentals reflect its long term potential, below analysis on Inmode Ltd. are made simple by VI app. According to VI Risk Rating, Inmode Ltd. is a medium risk investment in terms of financial and business aspects. VI App has detected 1 risk warnings in financial journal. Become a registered user to check it out.

VI Peers

The market for aesthetic medical device is highly competitive with InMode Ltd. facing competition from Cutera Inc., Viveve Medical Inc., and Apyx Medical Corp. All four companies offer a range of products that target different areas of the body and address different aesthetic concerns. InMode Ltd. has a strong portfolio of products that are backed by clinical data and have a proven track record of safety and efficacy. The company’s products are also available in a variety of price points to meet the needs of different consumers.

– Cutera Inc ($NASDAQ:CUTR)

Cutera Inc is a medical device company that provides aesthetic treatments to patients worldwide. Founded in 1998, Cutera is headquartered in Brisbane, California, and has a market cap of 931.59M as of 2022. The company’s Return on Equity is -111.73%. Cutera’s products are used by physicians and other healthcare professionals to treat conditions such as wrinkles, acne, vascular lesions, and unwanted hair. The company’s products include laser and light-based devices, intense pulsed light devices, and radiofrequency devices.

– Viveve Medical Inc ($NASDAQ:VIVE)

Viveve Medical Inc. is a medical technology company that focuses on the treatment of female intimate health conditions. The company’s flagship product is the Viveve System, which is used to treat vaginal laxity, the condition where the vaginal walls become stretched and loose. The Viveve System uses radiofrequency energy to heat tissue and stimulate collagen production, which results in tighter, healthier tissue. Viveve Medical Inc has a market cap of 6.19M as of 2022. The company’s Return on Equity is -179.17%. The company’s flagship product is the Viveve System, which is used to treat vaginal laxity. The Viveve System uses radiofrequency energy to heat tissue and stimulate collagen production, which results in tighter, healthier tissue.

– Apyx Medical Corp ($NASDAQ:APYX)

Apyx Medical Corp is a medical device company that develops, manufactures, and markets radiofrequency (RF) products for the global surgical market. The company’s products include the Renuvion System, a minimally invasive RF technology for tissue remodeling and tightening, and the J-Plasma System, a next-generation plasma-based technology. Apyx Medical Corp has a market cap of 149.01M as of 2022, a Return on Equity of -22.62%. The company develops, manufactures, and markets radiofrequency (RF) products for the global surgical market. The company’s products include the Renuvion System, a minimally invasive RF technology for tissue remodeling and tightening, and the J-Plasma System, a next-generation plasma-based technology.

Summary

InMode Ltd. is a medical aesthetics company that develops, manufactures, and markets minimally-invasive aesthetic treatments. The company’s products are used for body contouring, skin tightening, and facial rejuvenation. InMode Ltd. has a strong history of financial growth, reporting record revenue in its most recent quarter. The company’s stock price has also been on the rise, making it an attractive investment for those looking to profit from the growing medical aesthetics industry.